IL127930A - Use of (R) - Verapmil for the manufacture of a drug for the treatment of angina - Google Patents
Use of (R) - Verapmil for the manufacture of a drug for the treatment of anginaInfo
- Publication number
- IL127930A IL127930A IL12793097A IL12793097A IL127930A IL 127930 A IL127930 A IL 127930A IL 12793097 A IL12793097 A IL 12793097A IL 12793097 A IL12793097 A IL 12793097A IL 127930 A IL127930 A IL 127930A
- Authority
- IL
- Israel
- Prior art keywords
- verapamil
- angina
- treatment
- medicament
- manufacture
- Prior art date
Links
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 20
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 229960001722 verapamil Drugs 0.000 description 18
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 14
- SGTNSNPWRIOYBX-MHZLTWQESA-N (S)-verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-MHZLTWQESA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000000304 vasodilatating effect Effects 0.000 description 5
- 230000001848 cardiodepressant effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000036515 potency Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003257 anti-anginal effect Effects 0.000 description 2
- 239000003218 coronary vasodilator agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000002551 venodilator Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9616549.3A GB9616549D0 (en) | 1996-08-06 | 1996-08-06 | Therapeutic product and its use |
| PCT/GB1997/002095 WO1998005322A1 (en) | 1996-08-06 | 1997-08-06 | Verapamil as a medicament for the treatment of angina |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL127930A0 IL127930A0 (en) | 1999-11-30 |
| IL127930A true IL127930A (en) | 2001-08-08 |
Family
ID=10798127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12793097A IL127930A (en) | 1996-08-06 | 1997-08-06 | Use of (R) - Verapmil for the manufacture of a drug for the treatment of angina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5889060A (de) |
| EP (1) | EP0942719B1 (de) |
| JP (1) | JP2000515540A (de) |
| KR (1) | KR20000029768A (de) |
| AT (1) | ATE214923T1 (de) |
| AU (1) | AU721955B2 (de) |
| BR (1) | BR9711960A (de) |
| CA (1) | CA2260786A1 (de) |
| DE (1) | DE69711422T2 (de) |
| ES (1) | ES2174272T3 (de) |
| GB (1) | GB9616549D0 (de) |
| IL (1) | IL127930A (de) |
| PL (1) | PL331350A1 (de) |
| WO (1) | WO1998005322A1 (de) |
| ZA (1) | ZA977004B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092765A1 (en) | 2001-11-15 | 2003-05-15 | John Kelly | Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil |
| MX2009000923A (es) * | 2006-08-04 | 2009-03-09 | Agi Therapeutics Res Ltd | Metodos para tratar cuando menos una condicion que tiene receptor de mt1, receptor de 5ht2b, y actividad de canal de calcio tipo l. |
| WO2017198177A1 (en) * | 2016-05-20 | 2017-11-23 | Center Laboratories, Inc. | Method of treating hyperglycemia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4203547A1 (de) * | 1992-02-07 | 1993-08-12 | Knoll Ag | Verfahren zur racemattrennung von verapamil |
| GB9319918D0 (en) * | 1993-09-27 | 1993-11-10 | Chiros Ltd | Chiral compounds and their preparation |
| AU3778497A (en) * | 1996-08-06 | 1998-02-25 | Darwin Discovery Limited | Therapeutic utilities of verapamil enantiomers |
-
1996
- 1996-08-06 GB GBGB9616549.3A patent/GB9616549D0/en active Pending
-
1997
- 1997-08-06 EP EP97934643A patent/EP0942719B1/de not_active Expired - Lifetime
- 1997-08-06 AU AU37785/97A patent/AU721955B2/en not_active Ceased
- 1997-08-06 US US08/907,152 patent/US5889060A/en not_active Expired - Fee Related
- 1997-08-06 PL PL97331350A patent/PL331350A1/xx unknown
- 1997-08-06 BR BR9711960A patent/BR9711960A/pt not_active Application Discontinuation
- 1997-08-06 CA CA002260786A patent/CA2260786A1/en not_active Abandoned
- 1997-08-06 AT AT97934643T patent/ATE214923T1/de not_active IP Right Cessation
- 1997-08-06 ZA ZA977004A patent/ZA977004B/xx unknown
- 1997-08-06 DE DE69711422T patent/DE69711422T2/de not_active Expired - Fee Related
- 1997-08-06 JP JP10507727A patent/JP2000515540A/ja active Pending
- 1997-08-06 KR KR1019997000883A patent/KR20000029768A/ko not_active Withdrawn
- 1997-08-06 WO PCT/GB1997/002095 patent/WO1998005322A1/en not_active Ceased
- 1997-08-06 IL IL12793097A patent/IL127930A/en not_active IP Right Cessation
- 1997-08-06 ES ES97934643T patent/ES2174272T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU3778597A (en) | 1998-02-25 |
| ATE214923T1 (de) | 2002-04-15 |
| AU721955B2 (en) | 2000-07-20 |
| ZA977004B (en) | 1998-08-06 |
| CA2260786A1 (en) | 1998-02-12 |
| PL331350A1 (en) | 1999-07-05 |
| JP2000515540A (ja) | 2000-11-21 |
| IL127930A0 (en) | 1999-11-30 |
| EP0942719A1 (de) | 1999-09-22 |
| WO1998005322A1 (en) | 1998-02-12 |
| ES2174272T3 (es) | 2002-11-01 |
| BR9711960A (pt) | 1999-08-24 |
| DE69711422T2 (de) | 2002-10-31 |
| DE69711422D1 (de) | 2002-05-02 |
| KR20000029768A (ko) | 2000-05-25 |
| EP0942719B1 (de) | 2002-03-27 |
| GB9616549D0 (en) | 1996-09-25 |
| US5889060A (en) | 1999-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4248858A (en) | Sustained release pharmaceutical compositions | |
| EP0741567B1 (de) | Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen | |
| KR101718639B1 (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| JP2022539821A5 (de) | ||
| JPH11507063A (ja) | 梗塞後の死亡率を低下させるための抗不整脈化合物の使用 | |
| US20100105695A1 (en) | Method for enhancing insulin secretion | |
| TW201026684A (en) | Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy | |
| Reicher-Reiss et al. | Calcium antagonists in patients with heart failure: a review | |
| EP0942719B1 (de) | Verwendung von (r)-verapamil als medizin zur behandlung von angina | |
| US20050009897A1 (en) | Method of treatment | |
| Koylan et al. | Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS) | |
| JPH11246410A (ja) | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 | |
| Spiess et al. | High-dose sufentanil: four cases of sudden hypotension on induction | |
| Kaneko et al. | A novel ryanodine receptor 2 inhibitor, M201‐A, enhances natriuresis, renal function and lusi‐inotropic actions: Preclinical and phase I study | |
| Baky et al. | Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics | |
| US9126989B2 (en) | Compound and methods for treating long QT syndrome | |
| KR20040090400A (ko) | ｅＮＯＳ 발현에 기인하는 질병의 예방 또는 치료제 | |
| SK19332001A3 (sk) | Použitie antagonistov kortizolu v liečení srdcového zlyhania | |
| MXPA99001294A (en) | Verapamil as a medicament for the treatment of angina | |
| KR0136787B1 (ko) | 심장질환 치료에 쓰이는 프로파페논과 퀴니딘의 지속성 조성물 | |
| Liang et al. | Comparison of antianginal efficacy of nifedipine and isosorbide dinitrate in chronic stable angina: a long-term, randomized, double-blind, crossover study | |
| CN101657198A (zh) | 增强胰岛素分泌的雷诺嗪 | |
| JP5559696B2 (ja) | 糖尿病性腎症の治療剤 | |
| EA002380B1 (ru) | Антиишемическое средство | |
| Loughrey et al. | A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic action: Pre-clinical and phase I study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| MM9K | Patent not in force due to non-payment of renewal fees |